ODTX
NASDAQ HealthcareOdyssey Therapeutics, Inc. - Common Stock
Biotechnology
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $16.93 |
|---|---|
| 成交量 | 416,593 |
| 市值 | 798.66M |
| RSI(14日) | 40.0 |
| 52周最高 | $20.30 |
| 52周最低 | $15.35 |
| Forward P/E | -3.60 |
| Price / Book | -0.75 |
🎯 投资策略评分
ODTX 在各投资策略中的评分。分数越高,越符合该策略目标。
🔍 策略解读
最佳匹配: 🔪 Falling Knife (71/100) — 此策略 逆向投资(超卖 + 低于移动均线).
评分最低的策略: 🚀 Moon Shot (14/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 ODTX in your text
粘贴任何文章、记录或帖子 — 工具将提取 ODTX 以及每一个其他隐藏的股票代码。
免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-06-02.